Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

T2 Biosystems CS (TTOO)

T2 Biosystems CS (TTOO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,365
  • Shares Outstanding, K 21,043
  • Annual Sales, $ 7,190 K
  • Annual Income, $ -50,080 K
  • EBIT $ -42 M
  • EBITDA $ -41 M
  • 60-Month Beta 0.35
  • Price/Sales 1.02
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.89
  • Most Recent Earnings $-0.57 on 11/14/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 114.82%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 0.00% on 12/19/24
  • IV Low 0.00% on 12/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 9,401
  • Open Int (30-Day) 9,279

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +1,427,242.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3100 +13.48%
on 12/17/24
0.7000 -49.74%
on 12/02/24
-0.1582 (-31.02%)
since 11/22/24
3-Month
0.3100 +13.48%
on 12/17/24
2.1300 -83.48%
on 09/24/24
-1.7082 (-82.92%)
since 09/23/24
52-Week
0.3100 +13.48%
on 12/17/24
8.3799 -95.80%
on 12/28/23
-4.8682 (-93.26%)
since 12/22/23

Most Recent Stories

More News
T2 Biosystems Expands International Market Presence with Sale of Four T2Dx® Instruments to European Distributor

T2 Biosystems sold four T2Dx® Instruments to expand its international presence in sepsis-testing technology.Quiver AI SummaryT2 Biosystems, Inc. announced the sale of four T2Dx® Instruments to its European...

TTOO : 0.3500 (-2.57%)
T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

TTOO : 0.3500 (-2.57%)
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

TTOO : 0.3500 (-2.57%)
T2 Biosystems Extends Supplier Agreement with Vizient Through March 2026 for Rapid Sepsis Detection Products

T2 Biosystems extends its agreement with Vizient, enhancing hospital access to rapid sepsis diagnostics through 2026.Quiver AI SummaryT2 Biosystems, Inc. has announced the extension of its supplier agreement...

TTOO : 0.3500 (-2.57%)
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

TTOO : 0.3500 (-2.57%)
T2 Biosystems Announces Licensing Plans to Enhance Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

T2 Biosystems announced plans to license its technology for direct-from-whole-blood detection of sepsis-causing pathogens, aiming to expand market access.Quiver AI SummaryT2 Biosystems, Inc. has announced...

TTOO : 0.3500 (-2.57%)
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

TTOO : 0.3500 (-2.57%)
T2 Biosystems: Q3 Earnings Snapshot

T2 Biosystems: Q3 Earnings Snapshot

TTOO : 0.3500 (-2.57%)
T2 Biosystems Announces Third Quarter 2024 Financial Results

TTOO : 0.3500 (-2.57%)
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

TTOO : 0.3500 (-2.57%)

Business Summary

T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens,...

See More

Key Turning Points

3rd Resistance Point 0.3964
2nd Resistance Point 0.3775
1st Resistance Point 0.3638
Last Price 0.3500
1st Support Level 0.3312
2nd Support Level 0.3123
3rd Support Level 0.2986

See More

52-Week High 8.3799
Fibonacci 61.8% 5.2972
Fibonacci 50% 4.3450
Fibonacci 38.2% 3.3927
Last Price 0.3500
52-Week Low 0.3100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar